急性早幼粒细胞白血病的最新进展
Recent advances in acute promyelocytic leukaemia.
作者信息
Ng Chin-Hin, Chng Wee-Joo
机构信息
National University Cancer Institute, Singapore, Singapore.
出版信息
F1000Res. 2017 Jul 28;6:1273. doi: 10.12688/f1000research.10736.1. eCollection 2017.
Abstract
Acute promyelocytic leukaemia (APML) is a subtype of leukaemia arising from a distinct reciprocal translocation involving chromosomes 15 and 17, which results in the fusion gene. Over the past three decades, APML has been transformed from a highly fatal disease to a highly curable one. This drastic improvement is because of the introduction of a new treatment strategy with all-trans retinoic acid and, more recently, arsenic trioxide. The revolutionary treatment of APML has also paved the way for a new cancer treatment, which is genetically targeted therapy. In this review, we look into this amazing journey of transformation and provide recent advances in the management of APML.
摘要
急性早幼粒细胞白血病（APML）是白血病的一种亚型，由涉及15号和17号染色体的独特相互易位引起，这导致了融合基因的产生。在过去三十年中，APML已从一种高度致命的疾病转变为一种高度可治愈的疾病。这种巨大的改善得益于全反式维甲酸新治疗策略的引入，以及最近三氧化二砷的应用。APML的革命性治疗也为一种新的癌症治疗方法——基因靶向治疗铺平了道路。在这篇综述中，我们探究了这一惊人的转变历程，并介绍了APML治疗方面的最新进展。
相似文献
1
Recent advances in acute promyelocytic leukaemia.
F1000Res. 2017 Jul 28;6:1273. doi: 10.12688/f1000research.10736.1. eCollection 2017.
2
Acute promyelocytic leukaemia (APML) with cryptic PML-RARA fusion has a clinical course comparable to classical APML with t(15;17)(q24.1;q21.2) translocation.
Br J Haematol. 2019 Jul;186(1):155-157. doi: 10.1111/bjh.15738. Epub 2018 Dec 26.
3
How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy.
J Mol Endocrinol. 2022 Oct 11;69(4):T69-T83. doi: 10.1530/JME-22-0141. Print 2022 Nov 1.
4
Acute promyelocytic leukaemia with a novel translocation t(16;17)(q12;p13): a case report.
Malays J Pathol. 2016 Dec;38(3):311-313.
5
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.
6
Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia.
Acta Haematol. 2004;112(1-2):55-67. doi: 10.1159/000077560.
7
Role of Prophylactic Steroids in Differentiation Syndrome.
Cureus. 2022 Sep 24;14(9):e29531. doi: 10.7759/cureus.29531. eCollection 2022 Sep.
8
Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: case report.
J Int Med Res. 2014 Dec;42(6):1363-73. doi: 10.1177/0300060514540630. Epub 2014 Sep 15.
9
Chromosomal abnormality of acute promyelocytic leukemia other than -: a case report of acute promyelocytic leukemia with del(5q).
BMC Clin Pathol. 2016 Oct 4;16:16. doi: 10.1186/s12907-016-0038-4. eCollection 2016.
10
A complex translocation (1;17;15) with spliced short-type PML-RARA fusion transcripts in acute promyelocytic leukemia: A case report.
Exp Ther Med. 2019 Feb;17(2):1360-1366. doi: 10.3892/etm.2018.7091. Epub 2018 Dec 13.
引用本文的文献
1
Coagulation Abnormalities and Risk Assessment in Acute Promyelocytic Leukemia: An Experience From a Resource-Constraint Country.
Cureus. 2022 Jun 17;14(6):e26026. doi: 10.7759/cureus.26026. eCollection 2022 Jun.
2
Transcriptomic profiling of blood from autoimmune hepatitis patients reveals potential mechanisms with implications for management.
PLoS One. 2022 Mar 21;17(3):e0264307. doi: 10.1371/journal.pone.0264307. eCollection 2022.
3
G/M cell cycle arrest and apoptosis induced by COH-203 in human promyelocytic leukemia HL-60 cells.
Oncol Lett. 2021 Dec;22(6):815. doi: 10.3892/ol.2021.13076. Epub 2021 Sep 28.
4
AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia.
BMC Cancer. 2021 Jun 17;21(1):713. doi: 10.1186/s12885-021-08450-y.
5
Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies.
Life Sci Alliance. 2020 Apr 17;3(6). doi: 10.26508/lsa.201900577. Print 2020 Jun.
6
Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study.
Saudi Med J. 2019 Nov;40(11):1171-1176. doi: 10.15537/smj.2019.11.24584.
7
The SUMO Pathway in Hematomalignancies and Their Response to Therapies.
Int J Mol Sci. 2019 Aug 9;20(16):3895. doi: 10.3390/ijms20163895.
本文引用的文献
1
First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.
Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26461. Epub 2017 Jan 23.
2
Long-term outcome of acute promyelocytic leukemia treated with all--retinoic acid, arsenic trioxide, and gemtuzumab.
Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.
3
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
Leukemia. 2016 Dec;30(12):2430. doi: 10.1038/leu.2016.237. Epub 2016 Oct 7.
4
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
J Clin Oncol. 2017 Feb 20;35(6):605-612. doi: 10.1200/JCO.2016.67.1982. Epub 2016 Oct 31.
5
PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Leukemia. 2016 Oct;30(10):1987-1992. doi: 10.1038/leu.2016.122. Epub 2016 May 2.
6
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Ann Hematol. 2016 Apr;95(5):673-80. doi: 10.1007/s00277-016-2622-1. Epub 2016 Feb 26.
7
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.
8
Successful treatment of acute promyelocytic leukemia with a t(X;17)(p11.4;q21) and BCOR-RARA fusion gene.
Cancer Genet. 2015 Apr;208(4):162-3. doi: 10.1016/j.cancergen.2015.01.008. Epub 2015 Feb 2.
9
Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia.
N Engl J Med. 2014 Dec 4;371(23):2239-41. doi: 10.1056/NEJMc1412035.
10
Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial.
J Clin Oncol. 2014 Nov 20;32(33):3729-35. doi: 10.1200/JCO.2013.53.3570. Epub 2014 Sep 22.
Zotero 插件